SCHEMBL828165

SCHEMBL828165

CC1(N)C(=O)NC(=O)N(C2CCCCC2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 4/20 0.39
CYP2C19 P33261 4/20 0.36
CYP2C9 P11712 3/20 0.36
CYP3A4 P08684 2/20 0.36
CTSE P14091 1/20 0.36
BACE1 P56817 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP19A1 P11511 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5268829 0.79 LMNA (0.39) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL828578 0.79 ALDH1A1 (0.40) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL9337194 0.72 ALDH1A1 (0.40) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL10948791 0.71 ALDH1A1 (0.44) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL825848 0.70 TNF (0.37) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL5271146 0.68 ALDH1A1 (0.42) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL6231307 0.66 MAPT (0.47) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL27847078 0.66 OPRM1 (0.38) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL11153950 0.66 LMNA (0.40) LMNAPOLBGAAALDH1A1CYP2C19
SCHEMBL16865427 0.66 CYP2C19 (0.45) LMNAPOLBGAAALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004614-B1 TETRAHALOGENATED COMPOUNDS USEFUL AS INHIBITORS OF ANGIOGENESIS US GOV HEALTH & HUMAN SERV (US) 2016-10-19 EP disclosed
US-8143252-B2 Tetrahalogenated compounds useful as inhibitors of angiogenesis THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-03-27 US disclosed
US-20090186913-A1 Tetrahalogenated compounds useful as inhibitors of angiogenesis THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186913-A1 Tetrahalogenated compounds useful as inhibitors of angiogenesis VHL, TEK, FLT4 LMNA 4761/4885POLB 1657/4885GAA 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.